2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
29
Triple Negative Breast Neoplasms
13
Prostatic Neoplasms
13
Ovarian Neoplasms
12
Neoplasms
12
Neoplasm Metastasis
9
Fallopian Tube Neoplasms
6
Leukemia, Myeloid, Acute
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Carcinoma, Renal Cell
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Recurrence
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lung Neoplasms
2
Carcinoma, Ovarian Epithelial
2
mCRPC
1
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thrombocythemia, Essential
1
Solid Tumor
1
Sarcoma
1
Interventions
Doxorubicin
18
Ifosfamide
13
Radiotherapy
8
Paclitaxel
7
pazopanib
6
pembrolizumab
4
Gemcitabine
4
Filgrastim
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
spartalizumab
3
durvalumab
3
Sorafenib
3
Propranolol
3
Nivolumab
3
Ipilimumab
3
Imatinib Mesylate
3
Etoposide
3
Epirubicin
3
Docetaxel
3
Carboplatin
3
trebananib
2
regorafenib
2
cixutumumab
2
cemiplimab
2
carotuximab
2
brostallicin
2
belinostat
2
balstilimab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
talazoparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled